ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Late-Breaking 2021"

  • Abstract Number: L07 • ACR Convergence 2021

    Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM)

    Niti Goel1, Dulce Soler-Ferran2, Monette Coutreau2, Jorge Escobar3, Kate Courtemanche2, Merrilee Needham4 and Steven Greenberg5, 1Abcuro, Inc.; Duke University, Durham, NC, 2Abcuro, Inc., Newton, MA, 3Abcuro, Inc., Hayward, CA, 4Perron Institute, Murdoch University, Perth, Australia, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on microscopy…
  • Abstract Number: L08 • ACR Convergence 2021

    Association of Limited Health Literacy with Clinical and Patient-Reported Outcomes in Systemic Lupus Erythematosus: An Analysis from the Peer Approaches to Lupus Self-Management (PALS) Program

    Mithu Maheswaranathan1, Andrea Boan2, Viswanathan Ramakrishnan2, Hetlena Johnson3, Jillian Rose-Smith4, Clara Dismuke-Greer5, Leonard Egede6, Jim Oates2 and Edith Williams2, 1Duke University, Durham, NC, 2Medical University of South Carolina, Charleston, SC, 3LupusCSC, Columbia, SC, 4Hospital for Special Surgery, New York, NY, 5VA Palo Alto, Palo Alto, CA, 6Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Health literacy (HL) is an important social determinant of health defined as the ability to understand and use health information.  Limited HL is associated…
  • Abstract Number: L09 • ACR Convergence 2021

    A Prediction Model to Distinguish Patients with Multisystem Inflammatory Syndrome in Children

    Matthew Clark1, Danielle Rankin2, Alisa Gotte1, Alison Herndon1, William McEachern1, Andrew Smith3, Daniel Clark1, Edward Hardison1, Anna Patrick1, Lauren Peetluk1, Natasha Halasa1, James Connelly1 and Sophie Katz1, 1Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt University, Nashville, TN, 3The Heart Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL

    Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a rare consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MIS-C shares features with common infectious and…
  • Abstract Number: L10 • ACR Convergence 2021

    A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease

    joshua solomon1, Felix Woodhead2, Sonye Danoff3, Shana Haynes-Harp4, Tanvi Naik5, Cathie Spino5, Shelley Hurwitz6, Rie Maurer6, Daniel Chambers7, Martin Kolb8, Hiliary Goldberg6 and Ivan Rosas4, 1National Jewish Health, Denver, CO, 2University of Leicester, Leicester, United Kingdom, 3Johns Hopkins University, Baltimore, MD, 4Baylor College of Medicine, Houston, TX, 5University of Michigan, Ann Arbor, MI, 6Brigham and Womens Hospital, Boston, MA, 7University of Queensland, Brisbane, Australia, 8McMaster University, Hamilton, ON, Canada

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a prevalent and morbid condition leading to premature death in 10% of those affected. The TRAIL1 trial…
  • Abstract Number: L11 • ACR Convergence 2021

    Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study

    ELVIRA D'ANDREA1, Rishi Desai2, Mengdong He3, Robert Glynn4, Hemin Lee2, Michael Weinblatt2, Daniel Solomon5 and Seoyoung Kim2, 1Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3UCLA David Geffen School of Medicine, Los Angeles, CA, 4Brigham & Women's Hospital, Boston, MA, 5Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…
  • Abstract Number: L12 • ACR Convergence 2021

    Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function

    Michaela Koehm1, Tanja Rossmanith2, Ann Christina Foldenauer2, Eva Herrmann3, Herbert Kellner4, Uta Kiltz5, Jürgen Rech6, Gerd Burmester7, David Kofler8, Jan Brandt-Jürgens9, Christin Jonetzko10, Harald Burkhardt1 and Frank Behrens1, 1Rheumatology Goethe-University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 2Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 3Institute for Biostatistics and Mathematical Modeling, Goethe-Universität Frankfurt, Frankfurt, Germany, 4Praxis Prof. Dr. Kellner, München, Germany, 5Rheumazentrum Ruhrgebiet, Herne, Germany, 6Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, 7Charite Universitaetsmedizin Berlin, Germany and DRFZ, Berlin, Germany, 8Universitätsklinikum Köln, Med. Klinik I f. Innere Medizin Immunologische Ambulanz, Köln, Germany, 9Rheumatologische Schwerpunktpraxis im Ärztehaus am Walter-Schreiber-Platz, Berlin, Germany, 10Fraunhofer Insitute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany

    Background/Purpose: Methotrexate (MTX) is often used as first-line DMARD-therapy in active psoriatic arthritis (PsA). Randomized clinical trials usually require treatment failure or intolerance of csDMARD/MTX…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology